HUTCHMED DRC (HCM) Stock Analysis

HUTCHMED DRC (HCM) is a publicly traded company in the HEALTHCARE sector. It trades at $11.52, carries a market capitalization of $1.96B, a price-to-earnings ratio of 4.30. This page summarizes the public market data, fundamentals, and frequently asked questions for HCM, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $11.52
• Market Cap: $1.96B
• P/E Ratio: 4.30
• EPS: $2.65
• 52-Week High: $19.50
• 52-Week Low: $11.10

Market Sentiment

HUTCHMED DRC currently has a Bearish sentiment score of -0.20.

About HUTCHMED DRC

HUTCHMED (China) Limited is a prominent biopharmaceutical firm headquartered in Central, Hong Kong, specializing in the discovery, development, and commercialization of innovative targeted therapies and immunotherapies for oncology and immune-related conditions in global markets. The company boasts a strong pipeline and leverages advanced research capabilities alongside extensive clinical development expertise to meet significant unmet medical needs in cancer care. With strategic partnerships...

GNG Research Analysis

GNG Research scores HUTCHMED DRC (HCM) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for HCM.

Frequently Asked Questions

Does HCM pay dividends?

HUTCHMED DRC (HCM) does not currently pay a regular dividend.

What is HCM's P/E ratio?

HUTCHMED DRC has a price-to-earnings (P/E) ratio of 4.30.

What is HCM's market cap?

HUTCHMED DRC (HCM) has a market capitalization of $1.96B with a current stock price of $11.52.